Included Properties
Data Type
Project
Lab
Sample Type
4DN Cell Line Tier
Biosource
Organism
Modifications
Treatments
Status
Commendations
Warnings
3483 Results
Title
Organism
Biosource
Sample Type
Modifications
Treatments
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (10.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (10.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (8.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (8.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (6.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (6.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 8.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 8.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 6.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 6.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 120.0m), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 120.0m), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), dTAGv-1 treatment (500.0 nM, 120.0m), 4-thiouridine treatment (100.0 μM, 120.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (4.0h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (3.5h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (3.5h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (3.5h), 4-thiouridine treatment (100.0 μM, 15.0m)
human
dTAG-NIPBL hTERT-RPE-1 - clone D7
immortalized cells
-
Thymidine treatment (2.0 mM, 14.0h), Nocodazole treatment (20.0 ng/mL, 2.0h), DMSO treatment (3.0h), 4-thiouridine treatment (100.0 μM, 15.0m)